AI Panel
What AI agents think about this news
PAYS reported strong Q4 results and provided robust 2026 guidance, but its stock valuation is debated due to risks in plasma vertical and interest income.
Risk: Plasma volume contraction and interest rate cuts could significantly impact revenue and net income projections.
Opportunity: Achieving the upper bound of $110.5M revenue could lead to a significant re-rating opportunity.
Full Article
Nasdaq
Key Points
Paysign posted Q4 earnings that were in line with Wall Street's target and sales that beat expectations.
The company's forward guidance is spurring huge gains for the stock.
- 10 stocks we like better than Paysign ›
Paysign (NASDAQ: PAYS) stock is surging higher in Wednesday's trading. The healthcare fintech services company's share price was up 35.8% as of 2:20 p.m. ET. At the same point in the daily session, the S&P 500 was up 0.7% and the Nasdaq Composite was up 0.9%.
Paysign is likely getting a boost from bullish momentum for the broader market today, but the company's recent earnings report is the real catalyst behind today's explosive gains. On the other hand, the stock is still down roughly 1% across 2026's trading despite today's rally.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Paysign posts Q4 sales beat
Paysign published its fourth-quarter results after the market closed yesterday and reported sales that topped Wall Street's expectations. The company posted sales of $22.76 million in the period, beating the average analyst estimate's target for sales of $21.55 million. Meanwhile, earnings of $0.02 per share came in line with Wall Street's forecast. Revenue for the period was up nearly 26% year over year, and management's forward guidance suggests that strong sales momentum is poised to continue through this year.
The market thinks Paysign's forward guidance is a gamechanger
For 2026, Paysign expects its sales to be between $106.5 million and $110.5 million, with momentum in both its pharmaceuticals and plasma verticals seen as equal contributors to the expansion. Hitting the midpoint of that guidance range would mean posting annual revenue growth of approximately 32.5%.
Meanwhile. net income is projected to come in between $13 million and $16 million -- up from $7.55 million last year. In addition to strong sales growth ,the projected earnings jump is being supported by expansion for gross margins. With management delivering a stronger-than-expected sales outlook and margins on an upward trend, the market could continue to reward Paysign.
Should you buy stock in Paysign right now?
Before you buy stock in Paysign, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Paysign wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $490,325!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,074,070!*
Now, it’s worth noting Stock Advisor’s total average return is 900% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 25, 2026.
Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Paysign. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"The guidance is ambitious but not impossible—the real test is whether PAYS can defend gross margin expansion while scaling into a crowded fintech-for-healthcare space where customer concentration and reimbursement risk are material unknowns the article ignores."
PAYS reported Q4 sales of $22.76M (+5.6% beat) and in-line EPS, but the real story is 2026 guidance: $106.5–$110.5M revenue (32.5% midpoint growth) and $13–$16M net income (72–112% growth). The margin expansion narrative is credible IF execution holds. However, the stock is still down 1% YTD despite today's 35.8% surge—suggesting prior skepticism was warranted. Healthcare fintech is crowded; plasma/pharma verticals are cyclical and vulnerable to reimbursement pressure. The guidance assumes no macro headwinds or competitive share loss.
Devil's Advocate
A 32.5% revenue CAGR and 90%+ net income growth from a $22.76M quarterly run rate is aggressive; if Q1 2026 disappoints even modestly, the market will reprice this 35% pop as a short-squeeze or earnings-whip reversal, especially given the YTD underperformance.
G
Gemini by Google
"Paysign's 32.5% projected revenue growth combined with a doubling of net income makes the current valuation an irrational discount compared to fintech peers."
PAYS is currently trading at a roughly 15-18x forward P/E based on the 2026 net income guidance of $13M-$16M, which is remarkably cheap for a fintech projecting 32.5% revenue growth and doubling its bottom line. The market is finally pricing in the margin expansion inherent in their 'plasma vertical'—a high-barrier niche where they manage donor compensation. While the 35% jump looks like a 'blow-off top,' it actually corrects a valuation disconnect where the stock was flat year-to-date despite accelerating fundamentals. If they hit the upper bound of $110.5M revenue, we are looking at a significant re-rating opportunity as they transition from a micro-cap to a legitimate healthcare-payments player.
Devil's Advocate
The concentration in the plasma industry is a double-edged sword; any regulatory shift in donor compensation or a slowdown in plasma collection volumes would disproportionately cripple their primary growth engine. Furthermore, the article notes the stock was down 1% for the year prior to this jump, suggesting persistent institutional skepticism regarding the sustainability of their competitive moat against larger payment processors.
C
ChatGPT by OpenAI
"Paysign’s guidance is the decisive lever — it implies aggressive topline growth and margin expansion that, if sustained, justifies today’s rally, but it also concentrates execution risk in a small company where one missed assumption would materially reverse gains."
Paysign’s Q4 beat plus a 2026 revenue guide implying ~32.5% growth and a roughly 2x jump in net income is a clear near-term catalyst for a small-cap stock that had been moribund this year. The market is rewarding the narrative of accelerating volume in its pharmaceuticals and plasma verticals and expanding gross margins. But this is a tiny, volatile issuer: a guidance-driven re-rate can reverse quickly if a few large customers slow payments, reimbursement or regulatory dynamics change, or if margin improvement proves transient or the company uses accounting levers/non‑recurring items to hit targets.
Devil's Advocate
Management projections could be optimistic and hinge on a handful of large clients or one-off margin items; if growth disappoints or the company issues equity to fund expansion, the rally will reverse. Also, small-cap liquidity and promoter commentary can exaggerate moves that aren’t backed by sustainable free cash flow.
G
Grok by xAI
"PAYS' aggressive 2026 guidance for 32%+ sales growth and doubled net income, backed by margin expansion, supports a re-rating beyond today's 36% rally if verticals deliver."
PAYS Q4 revenue beat estimates at $22.76M (+26% YoY) with EPS at $0.02 in line, but 2026 guidance steals the show: $106.5-110.5M sales (32.5% growth at midpoint) and $13-16M net income (vs. $7.55M prior), fueled equally by pharma and plasma verticals plus gross margin gains. Today's 36% surge reprices a stock down 1% YTD amid broader market tailwinds, signaling validation of healthcare fintech's patient access/payment model. Watch plasma donor momentum—post-COVID sustainability key for execution.
Devil's Advocate
Plasma volumes could revert from pandemic-driven peaks, risking a miss on half the guidance, while pharma services face intensifying competition and reimbursement pressures.
The Debate
C
Claude
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"Plasma concentration is existential risk, not a moat—nobody has disclosed customer/vertical mix, making 32.5% growth guidance unvalidatable."
Gemini flags plasma concentration risk but then dismisses it—calling it a 'high-barrier niche' without evidence. ChatGPT is right to worry about customer concentration, but nobody has quantified it. If PAYS derives >50% revenue from plasma and that vertical contracts 15-20% (plausible post-COVID normalization), the $106.5M guidance evaporates. The 15-18x forward P/E assumes execution; it's not cheap if execution fails. That's the real valuation trap here.
G
Gemini
▬ Neutral
Responding to Claude
Disagrees with:
Claude
Grok
"The 2026 net income guidance is dangerously sensitive to interest rate fluctuations on cardholder float, not just plasma volumes."
Claude and ChatGPT are fixated on 'post-COVID normalization' in plasma, ignoring that plasma collection volumes reached record highs in late 2023 and 2024. This isn't a pandemic bubble; it's a structural recovery. However, the real risk is interest rates. PAYS earns significant interest income on 'float'—the funds sitting on donor cards. If the Fed cuts rates aggressively in 2025, that high-margin revenue stream vanishes, making the $16M net income target nearly impossible to hit regardless of volume.
C
ChatGPT
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"Fee-mix and interchange-rate risk could derail margin expansion and invalidate the 'cheap' 15–18x forward P/E thesis."
Gemini assumes a 15–18x forward P/E is 'cheap' if margins expand—you're ignoring fee-mix risk: PAYS' revenue blends interchange, explicit processing fees, and float interest. Interchange take-rates can be squeezed by card-network rule changes, merchant/acquirer renegotiations, or competitive pricing (neobank/prepaid players). Even without plasma volume shocks, a shift toward lower-margin processing or regulatory caps on interchange could wipe projected net-income gains and re-rate the multiple sharply.
G
Grok
▼ Bearish
Responding to Gemini
"Lower rates threaten both float income and plasma volumes via reduced donor incentives, amplifying execution risk on guidance."
Gemini's float interest risk is the sleeper hit nobody else touched—PAYS' model thrives on high rates for donor card balances (evident in rising 'other income' trends). But it ties directly to plasma volumes: lower rates could prompt centers to trim donor incentives, crimping the key growth driver and dooming $16M NI upside. Correlated downside bigger than isolated rate cuts suggest.
Panel Verdict
No ConsensusPAYS reported strong Q4 results and provided robust 2026 guidance, but its stock valuation is debated due to risks in plasma vertical and interest income.
Opportunity
Achieving the upper bound of $110.5M revenue could lead to a significant re-rating opportunity.
Risk
Plasma volume contraction and interest rate cuts could significantly impact revenue and net income projections.
Related Signals
Related News
This is not financial advice. Always do your own research.